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cense.Abstract Background: Anticancer chemotherapy is thought to be effective by means of direct cyto-
toxicity on tumor cells.Alternativemechanisms of efﬁcacy have been ascribed to several commonanti-
cancer agents; including cyclophosphamide (CTX) and capecitabine (Cap) when given at lower doses
for prolonged period (metronomic chemotherapy) postulating an antiangiogenic activity as well.
Aim of work: To evaluate the action and tolerability of metronomic chemotherapy (MC) and its
impact on serum vascular endothelial growth factor (VEGF) levels in metastatic breast cancer
(MBC) patients.
Patients and methods: In this study we evaluated the clinical efﬁcacy and tolerability of low dose,
capecitabine (500 mg twice daily) together with oral cyclophosphamide (CTX) (a dose of 50 mg once
daily) in patients withmetastatic breast cancer. Vascular endothelial growth factor (VEGF), an angio-
genic marker, was measured in the serum samples; at base line, and after 2 and 6 months of therapy.
Results: Sixty patients were evaluable. One achieved complete response (CR), 12 partial responses
(PR), and 21 stable diseases (SD), while 26 were with progressive disease (PD). The overall response
rate was 21.7%with overall disease control (CR, PR, and SD) 56.7%. Themedian time to progressioniation Oncology and Nuclear
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16 L.R. Ezz El-Arab et al.was 7 ± 2.59 months and overall survival 16 ± 8.02 months. Toxicity was mild, Palmar–plantar ery-
throdythesia was the most common side effect and was observed in 22 patients (37%), leucopenia
(G1 + 2) was the most common hematological toxicity, and it was reported in 27% of the cases.
The median VEGF level was signiﬁcantly declined after 2 and 6 months of therapy compared to the
base line among the patients with disease control (CR, PR, and SD). Inmultivariate logistic regression
analysis, patients with post-menopausal, positive hormonal receptors, negative HER-2/Neu, and one
metastatic site, were statistically signiﬁcant and have a better disease control rate.
Conclusions: MC induced drop in VEGF, and was effective, minimally toxic regimen for the
treatment of metastatic breast cancer patients.
ª 2011 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Metastatic breast cancer is a chronic disease requiring speciﬁc
strategies to control disease progression and related symptoms.
Neovascularization, or angiogenesis, is a rate-limiting step
during tumorigenesis that promotes tumor cell survival and
proliferation by ensuring a supply of oxygen and metabolites.
In breast cancer, access to the vasculature also provides means
for tissue invasion and metastasis to distant sites [1,2].
Inhibitors of angiogenesis are a new clinical class of drugs
with therapeutic potential in oncology [3]. However, deﬁning
the most effective dose and schedule for such treatment re-
mains a signiﬁcant hurdle to their optimal use in the clinic
[4]. Thus, the classic maximum tolerable dose (MTD)
approach, as deﬁned in the past for cytotoxic drugs, might
not be adequate or relevant for this class of drugs which in
general have considerably less toxicity than conventional cyto-
toxics used at MTD, and therefore may be used for prolonged
periods to obtain inhibition of new vessel growth, and, in turn,
tumor stabilization or shrinkage [5].
Chronic administration of continuous low doses of chemo-
therapy also referred to as ‘metronomic’ chemotherapy (MC)
has an effect on the breast tumor and other compartments,
mainly the vasculature postulating an anticarcinogenic
activity; among them, methotrexate, cyclophosphamide, cape-
citabine, and taxanes are the most studies drugs [6]. The
rationale for this approach is preventing effective recovery of
the damaged tumor vasculature. This implies that activated
tumor vascular endothelial cells may be more sensitive to lower
doses of chemotherapeutic drugs compared with normal or
cancer cells, when exposed in a frequent or continuous manner
[4].
As opposed to maximum tolerated dose (MTD) chemother-
apy, main targets of which are presumed to be proliferating
tumor cells, the main target of frequent or continuous low dose
metronomic chemotherapy are the endothelial cells of growing
vasculature of a tumor. In addition, low dose metronomic
chemotherapy has very favorable toxicity proﬁle. Omission
of prolonged drug-free periods is the key which form basis
for anti-angiogenic effects of low dose metronomic chemother-
apy regimens, as these breaks are the reasons of repair and
recovery from anti-angiogenic effect of chemotherapeutic
drugs on developing tumor blood vessels [7].
Capecitabine has proven activity in MBC pretreated with
anthracycline and taxane, lower doses (<1000 mg/m2 daily)
have a more favorable therapeutic index, when compared with
standard dosage [8]. Moreover, ﬁxed daily doses and continu-
ous (non-cyclic) dosing schedules have been demonstrated tobe well tolerated and active in MBC [9]. A synergistic effect
was observed with the metronomic combination of a ﬂuoro-
uracil prodrug and cyclophosphamides [10].
Given these considerations, we evaluated the efﬁcacy and
tolerability of metronomic low-dose capecitabine and oral
cyclophosphamide (CTX) combination in metastatic breast
cancer in phase II trial and impact of this regimen upon serum
vascular endothelium growth factor (VEGF) values when
assessed at the baseline and after 2 and 6 months of
chemotherapy.
Patients and methods
This prospective phase II study was conducted at Clinical
Oncology and Nuclear Medicine Department, Ain Shams Uni-
versity, in the period from June 2006 to March 2008. The study
was approved by the Medical Ethics Committee of Faculty of
Medicine, Ain Shams University, and written informed con-
sent was obtained from all participants.
Patient eligibility
Eligibility criteria included female patients with metastatic
breast cancer. At least one measurable tumor site (target
lesion), age >18 and 675 years, Eastern Cooperative
Oncology Group (ECOG) performance status 62, adequate
bone marrow reserve deﬁned as hemoglobin level P10 g%
white blood cells >4000 mm3 and platelets >100,000 mm3.
Adequate renal and liver functions deﬁned as serum creatinine
61.5 mg/dl, serum bilirubin <2 mg/dl and aspartate amino-
transferase up to three times the upper limit of normal level
with life expectancy at least 6 months and signed informed
consent. While exclusion criteria included pregnant or lactat-
ing patients, presence of cerebral or leptomeningeal metastasis,
ascites, pleural effusion or solitary bony lesion as the only sited
of disease, any impairment of gastrointestinal function, that
may interfere with oral drugs absorption, or serious concomi-
tant systemic disorders incompatible with study design.
Study evaluation and treatment plan
Baseline evaluation included clinical examination, chest X-ray,
computed tomography scan (CTS) of abdomen, bone nuclear
scan, electrocardiogram (ECG), in addition to complete bio-
chemical and hematological tests. Patients were treated with
capecitabine (500 mg) tablet twice daily together with cyclo-
phosphamide (CTX) orally at a dose of 50 mg once daily. Oral
antiemetic treatment was allowed. Treatment was given on
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response, patients with complete response (CR), partial re-
sponse (PR) or stable disease (SD) could receive treatment
until progression, unacceptable toxicity or patient refusal.
Cyclophosphamide and capecitabine were reduced by 50% in
case of grade P2 hematologic toxicity, cystitis, GI toxicity,
or hand–foot syndrome. To achieve a 50% dose reduction,
cyclophosphamide was administrated as one 50-mg tablet
every other day and capecitabine was administrated as one
500-mg tablet daily. Serum VEGF was determined at baseline,
after 2 and 6 months of treatment.
The change due to follow-up study, delta change (dC) was
calculated. It was deﬁned as follows: delta change (dC) =
(Post-pre)/Pre or the difference between post and pre as
regards pre values for each patient.
Evaluation of VEGF
Quantitative determination of the human VEGF concentra-
tion in the serum samples was done by quantitative solid phase
ELISA (Quantikine: R&D system, USA). Determination of
VEGF concentration was done according to manufacturer’s
instructions. Each sample was analyzed in triplicate and the
mean values were used as the ﬁnal concentration.
Study assessment
Hematological and biochemical tests were repeated every
28 days. Toxicity was evaluated according to National Cancer
Institute Common Toxicity Criteria (NCICT) version 3.0 [12].
Assessment of response was performed according to Response
Evaluation Criteria in Solid Tumor (RECIST) [13] after and
every 8 weeks of therapy, with appropriate test for each patient.
CR was deﬁned as the disappearance of all known lesions
on two separate measurements at least 4 weeks apart, PR
was deﬁned as P30% reduction in the sum of the products
of the perpendicular diameter of measurable bidimensional le-
sion, PD was deﬁned as 20% increase with no CR, PR or SD
documented before increased disease and SD was deﬁned as
neither PR nor PD criteria met.
The disease control rate was deﬁned as the proportion of
patients who achieved CRs, PRs or SD.
Study end points
The primary end point of the study was to assess the disease
control rate and was related with percentage reduction in
VEGF. Secondary objectives were to assess toxicity proﬁle of
this regimen, time to disease progression and overall survival.
Statistical analysis
SPSS statistical software package (V. 17, Chicago, IL) was
used for data analysis. The following tests were done:
(1) Fridmen’s test for comparison between numerical
variables with repeated measures and if signiﬁcant,
Wilcoxon signed rank test was applied for pair wise
comparison of non-parametric data with corrections of
P-values.
(2) Wilcoxon signed rank test for pair wise comparison of
non-parametric data with correlation of p-value.(3) Chi-square test to study the association between the cat-
egorical variables data.
Time to progression (TTP) and overall survival (OS) were
measured from the date of treatment start to the date of pro-
gression and the date of last follow-up or death, respectively,
and were assessed using the Kaplan–Meier product limit esti-
mate method. P-value less than 0.05 was considered signiﬁ-
cant. All tests were two sided.
Results
Patients characteristics
From June 2006 to March 2008, 60 eligible patients were en-
rolled into the study, the patient characteristics are shown in
Table 1. Their age ranged from 47 to 72 years, with a median
age of 61 years, the majority was post-menopause (87%). Per-
formance status score 2 was reported in 26 patients (43.3%),
positive hormonal status (ER or PR) was recorded in 32
patients (53.3%), while HER-2/Neu was negative in 44
patients (73.3%). One metastatic site was reported in 24
(40%) patients, two metastatic sites were reported in 28
(46.7) and the remaining have three or more metastatic sites.
The domain site of metastasis was bone (n= 28), followed
by liver (n= 27), and lung (n= 21). The median number of
prior chemotherapies was two; 27% had one, 53% had two,
and 20% had three or more prior chemotherapies lines for
metastatic setting. All patients had progressive disease at study
entry. Fifty-one of patients (85%) previously treated with
anthracycline and/or taxane containing regimens.
Treatment activity
One patient attained a CR, and partial response was detected
in 12 (20%) with an overall RR (21.7%). Twenty one patients
had SD with global disease control rates of 56.6%. Disease
progression was documented in 26 cases.
Global disease control rates were signiﬁcantly observed in
post-menopause patients and those with positive hormonal
and negative HER-2/Neu status. As well as in patients with
lung metastasis as compared to other metastatic sites
(Table 1).
After a median follow-up period of 16 months (ranged from
4 to 38 months) the median overall survival for all participants
was 16 ± 8.02 months (95%CI 13.06–17.28 months) (Fig. 1),
for responders (CR and PR) was 24 ± 10.01 months (95%
CI 17.08–28.63 months) and for SDs was 19 ± 8.12 months
(95%CI 16.08–18.65 months).
The median TTP was 7 ± 2.59 months (95% CI 6.93–9.93)
for whole group (Fig. 2).
VEGF measurements and relation with disease progression
Sixty patients had VEGF serum levels measured at baseline,
additional measurements were carried out after 2 months
(n= 60) and 6 months (n= 58), respectively, two patients re-
fused and lost follow-up. The median VEGF level in patients
with global disease control was signiﬁcantly decreased with
continuous treatment from 442 pg/ml at baseline to 369 pg/
ml at 2 months then to 295 pg/ml at 6 months (p< 0.001).
Although, the median VEGF level in patients with PD was
Table 1 Therapeutic response according to patient and tumor characteristics in patients with metastatic breast cancer.
Factors (n= 60) Maximum response X2, P-value
(CR, PR, SD) (n= 34) (PD) (n= 26)
Age (range 47–72)
60 years (n= 30) 18 (52.9%) 12 (50%) 0.271, 0.602
>60 years (n= 30) 16 (47.1%) 14 (50%)
Menopausal status
Pre-menopause (n= 8) 2 (5.6%) 6 (23%) 4.172, 0.03
Post-menopause (n= 52) 32 (94.4%) 20 (77%)
ER or PR
ve (n= 28) 8 (23.5%) 20 (77%) 12.902, <0.001
+ve (n= 32) 26 (76.5%) 6 (23%)
Her2/Neu
ve (n= 44) 32 (94.4%) 12 (46%) 15.084, <0.001
+ve (n= 14) 2 (5.6%) 12 (46%)
Performance status (PS)a
(O + 1) (n= 34) 26 (76.5%) 8 (30.8%) 17.778, <0.001
(O + 2) (n= 26) 8 (23.5%) 18 (69.2%)
Previous chemotherapy
1 (n= 16) 12 (35.3%) 4 (15.4%) 22.5, <0.001
2 (n= 32) 22 (64.7%) 10 (53.8%)
3 (n= 12) 0 (0%) 12 (30.8%)
No. of metastases
1 (n= 24) 20 (58.8%) 4 (16.7%) 17.54, <0.001
2 (n= 28) 14 (41.2%) 14 (50%)
3 (n= 8) 0 (0%) 8 (33.3%)
Metastatic site
Lung (n= 12) 12 (100%) 0 (0%) –b
Liver (n= 8) 4 (50%) 4 (50%)
Lung + Liver (n= 4) 0 (0%) 4 (100%)
Lung + Bone (n= 6) 6 (100%) 0 (0%)
Lung + Soft tissue (n= 8) 8 (100%) 0 (0%)
Liver + Bone (n= 10) 2 (20%) 8 (80%)
Lung + Liver + Bone (n= 4) 0 (0%) 4 (100%)
Liver + Bone + Soft tissue (n= 4) 0 (0%) 4 (100%)
a PS, performance status according to ECOG (Eastern Cooperation Oncology group); PR, estrogen receptor; PR, progesterone receptor.
b No p values because small number of cases within groups.
18 L.R. Ezz El-Arab et al.also signiﬁcantly decreased (p< 0.05) with treatment from
468 pg/ml at baseline to 445 pg/ml at 2 months then to
406 pg/ml at 6 months, the delta change of VEGF in patients
with disease control was signiﬁcantly higher (p< 0.001) than
in those with PD patients as evaluated after 2 months
(0.155 and 0.06, respectively) and 6 months of therapy
(0.365 and 0.102, respectively) Table 2.
Response and angiogenic activity
Median VEGF for CR and PRs (13 patients) was decreased
with treatment from 456 pg/ml at baseline to 340 pg/ml at
2 months then to 258 pg/ml at 6 months (p< 0.001). Simi-
larly, the median VEGF level in SD patients (n= 21)
decreased with treatment from 426 pg/ml at baseline to
385 pg/ml at 2 months then to 310 pg/ml at 6 months
(p< 0.001), as shown in Table 3. Moreover, the delta change
of VEGF in responding cases was signiﬁcantly higher than in
SD patients either after 2nd (0.210 and 0.120, respectively)
or 6th months of therapy (0.390 and 0.290, respectively).Treatment compliance
A total of 257 cycles (months) of therapy were administered
with median administration time per patients of 4 months
(range; 2–16 months). Only 13% of cycles were delayed and
10% of courses administered at reduced dosages.
The overall regimen was well tolerated. Palmar–plantar ery-
throdythesia was the most common side effect (Grades 1 and 2
in 36.7% of cases). Leucopenia (Grades 1 and 2) was the most
frequent hematological toxicity and was observed in 27
patients. Grade 3 elevation of serum transaminases was re-
ported in 8% of patients necessitating transient cessation of
Cap and 50% dose reduction in the subsequent cycles. All
the previous toxic effects were reversible. No treatment related
mortality or febrile neutropenia was recorded (Table 4).
Discussion
Metronomic chemotherapy (MC) regimens have been shown
to exert antiangiogenic activity, by blocking the supply of
Figure 1 Overall survival for the studied metastatic breast cancer patients.
Figure 2 Progression free survival for the studied metastatic breast cancer patients.
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cells. So, it delays both primary tumor and metastasis growth
[11]. Over the last few years, numerous studies evaluating MC
alone or in combination with other antiangiogenic agents in
advanced breast [4], prostate [14], and ovarian [15] cancer
among other tumor types [2,16,17] have been reported. MC
has emerged as an effective treatment with a major clinical
advantage: it minimizes the toxic side effects of the drugs
employed, thereby allowing their safe and long term adminis-
tration [18]. In the current study, a new schedule was designedwith metronomic administration of Cap and oral cyclophos-
phamide. This schedule has shown synergistic antitumor activ-
ity without signiﬁcant toxicity [10].
Unlike studies evaluating the activity of classic cytotoxic
agents, where shrinkage in tumor size is the objective, the ab-
sence of disease progression assumes a great importance as an
end point in clinical trials using MC. Accordingly, our results
revealed that more than half of the patients included in the
trial are likely to beneﬁt from this treatment (CR,
PR + SD= 57%). It is also encouraging that the results we
Table 2 Serum VEGF concentrations (pg/ml) at baseline, 2 months and 6 months after treatment according to disease control in patients with metastatic breast cancer.
VEGF (pg/ml) Disease response P-value
Non-progressive (PR, CR, SD) median
(range)
Progressive disease (PD) median
(range)
Base line 442 (437.92–461.31) (n= 34) 468 (461.58–489.26) (n= 26)
2 months 369 (326.17–372.05) (n= 34) 445 (432.65–452.63) (n= 26)
6 months 295 (247.26–301.07) (n= 34) 406 (380.35–420.25) (n= 24)
Signed-rank test of VEGF between base line and
2 months
P< 0.001 P< 0.001
Signed-rank test of VEGF base line and 6 months <0.001 P< 0.001
Delta change of VEGF between base line and 2 months 0.155 (0.1659 to 0.2719) 0.060 (0.0488–0.0639) <0.001
Delta change of VEGF between base line and 6 months 0.365 (0.3206 to 0.4494) 0.102 (0.2021–0.1150) <0.001
Signed-rank test between 2 months and 6 months P< 0.0001 P= 0.0001
Table 3 Serum VEGF concentrations (pg/ml) at baseline, 2 months and 6 months after treatment according to therapeutic response in patients with metastatic breast cancer.
VEGF (pg/ml) Therapeutic response P-value
Complete and partial response (CR, PR)
median (range)
Stable disease (SD) median
(range)
Base line 456 (435.5–458.8) 426 (432.7–469.6)
2 months 340 (272–351) (PR = 13) 385 (347.6–398.3) (SD = 21)
6 months 258 (177–265.4) (CR = 1, PR = 12) 310 (280–335.5) (SD = 21)
Signed-rank test of VEGF base line and
2 months
Z= 3.3, P= 0.001 Z= 4.11, P< 0.001
Signed-rank test of VEGF base line and
6 months
Z= 3.3, P= 0.001 Z= 4.11, P< 0.001
Delta change of VEGF between base line and
2 months
0.210 (0.3930–0.2041) 0.120 (0.2267 to 0.1097) Z= 3.184, P= 0.001
(HS)
Delta change of VEGF between base line and
6 months
0.390 (0.6042–0.4043) 0.290 (0.3809 to 0.2373) Z= 2.794, P= 0.005
(HS)
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Table 4 Toxicity of the treatment in patients with metastatic breast cancer.
Toxicity Grade I No. (%) Grade II No. (%) Grade III No. (%) Total No. (%)
Leucopenia 16 (27%) 2 (3.3%) 1 (1.7%) 19 (32%)
Neutropenia 7 (12%) 3 (5%) – 10 (17%)
Thrombocytopenia 2 (3.3) – – 2 (3.3)
Anemia 13 (17%) 3 (5%) – 16 (26.7%)
Nausea and vomiting 12 (20%) 5 (8%) – 17 (28.3%)
Diarrhea 9 (15%) 3 (5%) – 12 (20%)
Hand and foot syndrome 19 (32%) 3 (5%) – 22 (36.7%)
Mucositis 7 (12%) 1 (1.7) – 8 (13.3%)
› Transaminases 9 (15%) 3 (5%) 5 (8%) 17 (28.3%)
Alopecia 1 (1.7%) – – 1 (1.7%)
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median VEGF level among the non-progressed group from
442 at the base line to 369 after two months then 295 after
6 months, signifying the usefulness of this regimen. These re-
sults conﬁrm previous studies [18,19].
Another important aspect of our results relates to the re-
sponse rate with chronic low-dose treatment of the chemother-
apeutic drugs that we studied. As reported in Table 3, the
median VEGF level for patients with CR or PR was declined
from 456 at the base line to 340 after 2 months the 258 after
6 months (at P= 0.001). Similarly those with SD their median
VEGF level were signiﬁcantly reduced, which emphasizes the
great response of the patients included in the trial and advan-
tage of using MC in reducing the VEGF level. VEGF is the
ligand for the VEGF receptor 2 and has been recognized as
a key potential target for the pharmacological inhibition of
tumor angiogenesis. Several in vitro and in vivo studies have
indicated that values of VEGF can be reduced after treatment
with agents inducing an antiangiogenic activity [19–21], and
that VEGF can be considered as a marker of the regulation
of angiogenic factors [22].
Our results strengthen the conclusion that the antitumor
effects of low-dose metronomic chemotherapy are attributable,
at least in part, to a mechanism involving inhibition of tumor
blood vessel formation. In addition to antiangiogenic mecha-
nisms in which fully differentiated endothelial cells are
growth-inhibited and/or killed by metronomic low-dose
chemotherapy, an antivasculogenic process may also be in-
volved that is mediated through effects on reducing circulating
endothelial progenitors (CEP) mobilization and viability [23].
The palliative goal of treatment in MBC and the achieve-
ment of symptomatic control and maintenance of quality of
life are desirable treatment end points. Accordingly, MC has
revealed several new and important aspects. These include
the success of the treatment strategy on blocking angiogenesis
(effect of CTX) and improving therapeutic index (Cap) [8].
Importantly, this regimen lacks major toxicities (bone marrow
suppression mucositis or hair loss). Thus, it may represent the
paradigm of effective/low-toxic anticancer therapy [10,24].
The identiﬁcation of patients who might beneﬁt fromMC is
crucial for optimization of the treatment strategy. Postmeno-
pausal status, expression of steroid hormone receptors; lung
metastasis as well as single site of disease were signiﬁcantly
observed more in patients who achieved clinical beneﬁt. These
results are in line with previously reported data [18,19]. In our
series, the recorded lower efﬁcacy of MC in heavily pretreated
patients might be related to redundancy of angiogenic factorsvascular remodeling related to previous exposure to chemo-
therapy, angiogenesis-independent tumor growth, increased
hypoxia tolerance all lead to acquire resistance [25].
Combination of anti-angiogenic drugs as bevacizumab with
MC induce remarkable responses with sustained tumor regres-
sion in advanced breast cancer [15,22]. But for economic con-
sideration it could not be used on regular basis in MBC
patients.
In conclusion, low-dose, oral CTX, and Xeloda demon-
strated signiﬁcant efﬁcacy in metastatic breast cancer and pro-
vided disease control for a signiﬁcant proportion of patients.
Increased attention to patients’ quality of life favors the use
of an active oral treatment. The low burden of personal costs
(subjective toxicity and infrequent visits to care providers) and
the possibility to continue the treatment for several months in
responders (as often required for patients with advanced breast
cancer who respond positively to chemotherapy). VEGF can
be considered as predictive marker of response to MC.
Although such preliminary results are encouraging, they need
to be conﬁrmed in much larger, controlled and prospective
randomized clinical trials to substantiate the survival beneﬁt
of the less toxic low-dose/continuous chemotherapy protocols
over the standard MTD protocols.References
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